ClinicalTrials.gg
RecruitingNCT07552831T3Updated Nov 19, 2026

Trapeziometacarpal Joint Arthroplasty Versus Trapeziectomy for Thumb Carpometacarpal Osteoarthritis

An interventional study of trapeziometacarpal arthroplasty and Trapeziectomy in Thumb Osteoarthritis, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 19, 2026Now RecruitingFirst site in Sweden+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Osteoarthritis with a site in Sweden — 12 open to participants now, 25 under way, none of them phase 3. Osteoarthritis · Sweden.

Planned enrollment
40th of 57
64 · median 98
Started
2026
with 2 others
No phase
41 of 78
6 open now
Primary completion
2028-12
later than 15 of 24 live
Registered
77th of 78
by date
Lead sponsor
3 of 78
Sahlgrenska University Hospital

Among the 78 studies in Osteoarthritis with a site in Sweden, this one is the 40th largest by planned enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2026, is one of 41 with no phase, reaches primary completion later than 15 of the 24 other live ones, and was the 77th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 78 studies in Osteoarthritis with a site in Sweden are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Osteoarthritis with a site in Sweden, or all of them as a file.
02

Study summary

Thumb carpometacarpal osteoarthritis is common and may cause severe pain and functional limitation. Trapeziectomy is widely used, whereas prosthetic arthroplasty may offer faster early recovery. However, detailed information on early postoperative and long-term radiological outcomes remains limited.

This is a single-centre, blinded randomised controlled trial at Sahlgrenska University Hospital, Gothenburg, Sweden. Adults aged 18-69 years with symptomatic thumb carpometacarpal osteoarthritis (Eaton grade 2-3) refractory to at least 3 months of non-operative treatment will be randomised 1:1 to trapeziometacarpal prosthetic arthroplasty or trapeziectomy. The primary outcome is day-by-day pain (registration on a numeric rating scale NRS, 0-10). Secondary outcomes include day-by-day analgesic consumption for 90 days, orthosis use after cast removal, patient-reported function (HQ-8, QuickDASH, and Nelson score) at 30, 45, 60, 75 and 90 days, assessor-measured range of motion and strength at 45 and 90 days, and long-term clinical follow-up at 6 months and 1, 2, 5 and 10 years. Cone beam computed tomography will be obtained in the arthroplasty group at 1 week postoperatively as reference and at 6 months and 1, 2, 5 and 10 years to assess implant position, migration and loosening. The target sample size is 64 participants (32 per group), providing 95% power to detect a 1-point between-group difference on the pain scale. Analyses will follow the intention-to-treat principle.

Read the detailed description

Aim and objectives The primary aim is to compare early postoperative pain trajectories after CMC-1 arthroplasty versus trapeziectomy for symptomatic thumb carpometacarpal osteoarthritis, using day-by-day patient-reported pain measurements during the first 90 postoperative days.

Secondary aims are to compare:

(i) Daily analgesic consumption during the first 90 postoperative days (ii) Orthosis use after cast removal (iii) Patient-reported hand/upper limb function using HQ-8, QuickDASH and Nelson score (iv) Blinded clinical measures of thumb range of motion, grip strength and pinch strength (v) Long-term clinical outcomes up to 10 years. Additionally, in the arthroplasty group, a long-term aim is to evaluate migration and radiological signs of implant loosening using cone beam computed tomography (CBCT). Similarly, in the trapeziectomy group, CBCT will be used to monitor and quantify metacarpal 1 proximal migration.

This protocol has been prepared in accordance with SPIRIT 2025 guidance [18], and includes a PRO EDI participant characteristics (Table 1).

Trial design This is a single-centre, assessor-blinded randomised controlled trial (RCT) with 1:1 allocation to prosthetic CMC-1 arthroplasty or trapeziectomy.

Study setting The study will be conducted at the Hand Surgery Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden. All operations will be performed by surgeons experienced in both techniques at least level 3 according to Giddins-Tang classification [19] and have at minimum overcome the previously described learning curve thresholds [20,21].

Eligibility criteria

Inclusion criteria:

  • Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and/or corticosteroid injections).
  • Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-4.
  • For Eaton grade 2, age ≥50 years.
  • Age 18-69 years.
  • Provision of written informed consent.

Exclusion criteria:

  • Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint).
  • Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis).
  • Post-traumatic thumb carpometacarpal osteoarthritis.
  • Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand.
  • Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus).
  • Osteoporosis/osteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty).
  • Ongoing systemic corticosteroid treatment.
  • Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis).
  • Cognitive impairment preventing reliable participation.
  • Ongoing, or suspected ongoing, alcohol or drug misuse.
  • Insufficient Swedish language proficiency to complete the questionnaires.

Participant identification, recruitment and consent Potential participants will be identified among patients referred for surgical evaluation of symptomatic thumb carpometacarpal osteoarthritis at the study site. Eligible patients will receive verbal and written information about the study. Written informed consent will be obtained before any study-specific data collection.

At baseline, participants will complete the HQ-8, QuickDASH and Nelson score questionnaires. Baseline demographic characteristics will be recorded in line with the PRO

03

Conditions studied

  • Thumb Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and/or injections).
  • Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-3.
  • For Eaton grade 2, age ≥50 years.
  • Age 18-69 years.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint).
  • Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis).
  • Post-traumatic thumb carpometacarpal osteoarthritis.
  • Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand.
  • Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus).
  • Osteoporosis/osteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty).
  • Ongoing systemic treatment.
  • Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis).
  • Cognitive impairment preventing reliable participation.
  • Ongoing, or suspected ongoing, alcohol or drug misuse.
  • Insufficient Swedish language proficiency to complete the questionnaires.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Trapeziometacarpal joint arthroplasty

    Implantation of the Touch® CMC-1 prosthesis

    Procedure: trapeziometacarpal arthroplasty

  • Active comparator
    Trapeziectomy

    Surgical excision of the trapezium

    Procedure: trapeziometacarpal arthroplasty · Procedure: Trapeziectomy

Interventions

  • Proceduretrapeziometacarpal arthroplasty

    Participants allocated to arthroplasty will undergo implantation of the Touch® CMC-1 prosthesis according to routine practice at the study site. Surgery will be performed by experienced hand surgeons. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free.

  • ProcedureTrapeziectomy

    Participants allocated to trapeziectomy will undergo surgical excision of the trapezium without tendon interposition according to routine practice at the study site. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free

06

What researchers measure

Primary outcomes

  1. Pain level

    Patient-reported pain at the thumb base, measured on a 0-10 numeric rating scale (0 = no pain, 10 = worst imaginable pain).

    Time frame: daily for three months

Secondary outcomes

  1. Analgesics used

    Daily registration of analgesic consumption

    Time frame: daily for three months

  2. Use of Orthosis

    • Orthosis use and perceived importance recorded weekly after cast removal

    Time frame: Daily for three months

  3. Patient-reported thumb symptoms

    measured with Nelson score (a disease specific questionnaire)

    Time frame: at 30, 45, 60, 75 and 90 postoperative days

  4. Patient-reported upper extremity function

    measured with QuickDASH questionnaire

    Time frame: at 30, 45, 60, 75 and 90 postoperative days

  5. Patient-reported hand function

    measured with HQ-8 questionnaire

    Time frame: at 30, 45, 60, 75 and 90 postoperative days

  6. Range of motion

    Objective thumb range of motion (radial and volar abduction) measured by a blinded assessor

    Time frame: at 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.

  7. Strength

    Grip strength and pinch strength measured by a blinded assessor

    Time frame: at 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.

  8. Migration of prosthesis on cone beam computed tomography

    • Long-term radiological assessment with CBCT in the arthroplasty group to assess implant position, migration and loosening and to assess metacarpal 1 migration in the trapeziectomy group

    Time frame: at 6 months and 1, 2, 5 and 10 years (with a 1-week reference scan).

07

Study locations

1 of 1 sites recruiting
  • Sahlgrenska University Hospital, Department of Hand Surgery
    Gothenburg, Sweden
    Recruiting
    • Joakim Stromberg, MD, PhD · Contact+46768341327
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 27 months is close to that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 27, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2038
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in Sweden
Show site
  • Sahlgrenska University Hospital, Department of Hand Surgery · Gothenburg, Sweden
Nov 19, 2026
Start date
Sep 1, 2026→Sep 30, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Sweden
    Show site
    • Sahlgrenska University Hospital, Department of Hand Surgery · Gothenburg, Sweden
    Start date Sep 1, 2026→Sep 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07552831
Responsible party
Joakim Stromberg (Associate Professor, Sahlgrenska University Hospital) — Principal investigator
First posted
Apr 27, 2026
Start date
Sep 30, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2038 (estimated)
Last update
Nov 19, 2026

Study contacts

Joakim Stromberg, Md,PhD
Contact
joakim.stromberg@vgregion.se
+46768341327
Victoria Wängberg, MD
Contact
victoria.wangberg@vgregion.se
+46739804631
Joakim Stromberg, MD, PhD
principal investigator · Sahlgrenska University Hospital, University of Gothenburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion